We analyzed the genomic events, tumor microenvironment characteristics, and clinical outcomes associated with CDKN2A/BHD LUAD and identified a mechanism involving IFN‐I that leads to poor prognosis. This evidence concerns the gene CDKN2A and neoplasm.